SELLAS Life Sciences Group is part of the biotechnology industry and trades as part of the healthcare sector. The company CEO is Angelos Stergiou. SELLAS Life Sciences Group Inc is a biopharmaceutical company. The company is engaged in the development of novel cancer immunotherapies for a broad range of cancer indications. Its pipeline products are Galinpepimut-S and NeuVax.



Previous Intraday Performance:

The SLS shares had a previous change of -2.23% which opened at 0.39 and closed at 0.38. It moved to an intraday high of 0.42 and a low of 0.37.

SeekingAlpha:  SELLAS Life Sciences beats by $0.01

Historical Performance:

Over the last five trading days, SLS shares returned -19.73% and in the past 30 trading days it returned -61.93%. Over three months, it changed -70.59%. In one year it has changed -92.91% and within that year its 52 week high was 5.35 and its 52 week low was 0.37. SLS stock is 1.73% above its 52 week low.

Our calculations result in a 200 day moving average of 1.26 and a 50 day moving average of 0.82. Right now, SLS stock is trading -70.12% below its 200 day moving average and may not be a great opportunity to buy as it may continue to trend down.

SeekingAlpha:  SELLAS Life Sciences beats by $0.01

Liquidity:

The company has a market cap of $9.5m with 25.2m shares outstanding and a float of 23.2m shares. Trading volume was 895,458 shares and has experienced an average volume of 704,754 shares. Our calculation, using the current average volume and close price, leads me to believe that the liquidity is bad, highly speculative and an investor may want to avoid this stock.

Earnings:

The last annual reported EPS for SELLAS Life Sciences Group was -3.86 which ended on 31st of December 2018. Based on 1 analyst estimate, the estimated EPS for the next quarter is -0.27.

Below was the last reported quarterly diluted earnings per share:

1stQtr 2019Reported 05-15-2019: -0.22
4thQtr 2018Reported 03-22-2019: -0.61
3rdQtr 2018 -0.53
2ndQtr 2018 -1.26
1stQtr 2018 -1.67

The next earnings report will be: 06-21-2019

The growth of the EPS is critical in understanding the current valuation of SELLAS Life Sciences Group.



Indicators Also to Watch:

Based on the latest filings, there is 19.60% of institutional ownership.

The beta was calculated to be 1.78.

Business Wire:  Western Alliance Bancorporation Authorizes Initiation of Regular Quarterly Dividend Commencing in Third Quarter 2019

Fundamental Numbers:

Based on last reported financials, the company’s return on assets is -159.66% and price-to-book is 3.29.

Company Score Card:

Results are out of six:
 2  : Growth Expectations Result
 2  : Financial Safety Result
 0  : Past Performance Result
 0  : Valuation Result
 0  : Dividend Safety Result
 1  : Overall Result

Related Tags: , , ,

Jake McWilliams
I am an independent trader, analyst and algorithmic trading expert, having worked both for the sell side (brokerage) and the buy side (fund administration). I have been trading professionally for about 20 years. I trade stocks and forex and I play both long and short positions in underlying asset or through options. I have experience with discretionary and fully automated systems (Metatrader and Quantshare).

LEAVE A REPLY

Please enter your comment!
Please enter your name here